— Onconova Therapeutics (NASDAQ: ONTX) reported FY2019 net loss of $1.49 per share, vs. $4.99 per share last year.
— Net loss was $21.5 million compared to $20.4 million last year.
— Research and development expenses were $15.5 million versus $16.9 million for 2018.
— Cash and cash equivalents as of December 31, 2019, totaled $22.7 million, compared to $17 million as of December 31, 2018.
While the markets got a boost a couple of weeks ago after Congress passed the new stimulus bill, investors seem to have adopted a cautious stance as details of the
Delta Air Lines (NYSE: DAL) reported fourth quarter 2020 earnings results today. Operating revenues fell 65% year-over-year to $4 billion. The company reported a GAAP net loss of $755 million,
Aphria Inc. (NYSE: APHA) reported second-quarter 2021 earnings results on Thursday. Revenues were C$160.5 million, an increase of 33% compared to the previous year. On an adjusted basis, the company reported earnings